How to Spot a Scam Peptide Vendor

Most peptides sold online are unapproved drugs, frequently labeled “research use only” and shipped with little independent oversight. That gap is where scams live. This guide is harm-reduction, not an endorsement: Compound Codex sells nothing and links to no vendor. It is not medical advice.

The “research use only” label is not a safety badge

Vendors lean on “research use only” or “not for human consumption” disclaimers as legal cover. The FDA has been explicit that this language does not exempt a product the agency deems intended for human use, and that an unapproved drug carries no assurance of its identity, purity, potency, or safety. Such products may be contaminated, counterfeit, sub-potent, or contain entirely different ingredients. That risk is sharpest with injectables, which bypass the body’s defenses against toxins and microbes. The FDA has issued warning letters to peptide sellers — for example, USApeptide.com in February 2025, over the sale of unapproved and misbranded semaglutide and tirzepatide. A vendor implying any peptide is “FDA-approved for humans” is misrepresenting current status.

It is also worth knowing how fast this regulatory picture is moving. In 2023 the FDA flagged 19 peptides as too risky for pharmacy compounding (the agency’s “Category 2”). In April 2026, under HHS Secretary Robert F. Kennedy Jr., the FDA removed 12 of those peptides — including BPC-157 — from Category 2 after the nominations supporting their restriction were withdrawn. Removal is not approval: those substances are not on the 503A list of bulk substances cleared for compounding, and several (BPC-157 among them) are scheduled for advisory-committee review in July 2026. Until and unless that process clears a specific peptide for compounding, it remains an unapproved drug for human use. Any vendor claim that a peptide is “now FDA-approved” or “off the banned list, so it’s safe” misstates where things actually stand.

Missing or meaningless certificates of analysis (COAs)

A real COA is third-party evidence of what is in the vial. Treat these as warning signs:

No COA, or one not tied to your batch. A legitimate COA names a specific lot or batch number that matches what you received. A single generic certificate reused across all products tells you nothing about your vial.
No identity test. HPLC reports purity — the share of the sample that is one compound. It cannot confirm which compound that is; only mass spectrometry verifies the molecule’s identity by its molecular weight. A sample can be highly pure by HPLC and still be the wrong peptide, so purity figures with no MS leave identity unverified.
Text-only results with no chromatogram or spectrum. Numbers without the underlying graphs are trivial to fabricate.
Suspiciously clean numbers. Real assays report values like 98.47%, not a tidy “99%” or “100%.”
No issuing lab named, or an unverifiable one. Independent, accredited labs (e.g., ISO/IEC 17025) have no stake in the result. An in-house or anonymous COA carries a conflict of interest.

A COA also says nothing about sterility, endotoxins, or heavy metals unless those were specifically tested — and most aren’t.

Health and “miracle” claims

Disease-treatment, anti-aging, or rapid fat-loss promises are both a scientific and a legal red flag. Selling an unapproved compound while claiming it treats or cures anything is precisely what triggers FDA enforcement, and a vendor willing to break that rule is signaling how it treats the others. Be especially wary of GLP-1 “alternatives”: the FDA has seized counterfeit Ozempic from the U.S. supply chain, logged hundreds of adverse-event reports tied to compounded semaglutide and tirzepatide, and warned that some products use unapproved salt forms that are not the active ingredient in the approved drug. Testing of fraudulent compounded “semaglutide” has, in some cases, found products that contained no semaglutide at all.

Fake reviews and manufactured trust

Since the FTC’s Rule on the Use of Consumer Reviews and Testimonials took effect on October 21, 2024, it is illegal to create, buy, or sell fake or AI-generated reviews, to give incentives conditioned on a positive rating, to post undisclosed insider reviews, or to suppress honest negative ones — with civil penalties up to roughly $53,000 per violation. Signs you’re looking at manufactured trust: a wall of five-star reviews posted in a tight window, generic praise with no specifics, identical phrasing across “different” users, off-site forum accounts that only ever endorse one vendor, and threats against critics.

Sketchy payment and shipping

Payment and logistics often reveal a scam before the product arrives. Watch for crypto-only or wire/Zelle/gift-card-only checkout with no card option (legitimate card processors offer chargeback protection, which fraud operators avoid), prices far below everyone else, no verifiable business address, support only through an encrypted chat app, and pressure tactics like “last batch” countdowns. Vague shipping, no cold-chain handling for products that need it, and silence when a package never arrives round out the pattern.

Bottom line

No single red flag is proof, but they cluster. The strongest tells are a batch-specific third-party COA with both HPLC and mass-spec data, the absence of medical claims, and normal payment options. Missing those, assume the contents are unverified — and remember that for human use, these products remain unapproved drugs with no assurance of identity, purity, or safety.